BioStock: Final study results - ColdZyme reduces illness duration and alleviates symptoms
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Pressmeddelande

BioStock: Final study results - ColdZyme reduces illness duration and alleviates symptoms

An independent investigator-initiated study from the University of Kent demonstrates that Enzymatica’s mouth spray ColdZyme reduces the duration of upper respiratory tract infections by up to five days in endurance athletes, enabling faster return to training. Additionally, ColdZyme alleviates symptoms and decreases the viral load of rhinovirus, the most common cause of a cold. Principal investigator Glen Davison shared insights on these results in an interview with BioStock.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/09/final-study-results-coldzyme-reduces-illness-duration-and-alleviates-symptoms/

This is a press release from BioStock - Connecting Innovation & Capitalhttps://www.biostock.se

Nyheter om Enzymatica

Läses av andra just nu

Om aktien Enzymatica

Senaste nytt